IntraVenous Fluid GENeration for Exploration Missions (IVGEN) - 02.25.15
IntraVenous Fluid GENeration for Exploration Missions (IVGEN) demonstrates the capability to purify water to the standards required for intravenous administration, then mix the water with salt crystals to produce normal saline. This hardware is a prototype that will allow flight surgeons more options to treat ill or injured crewmembers during future long-duration exploration missions. Science Results for Everyone
Information Pending Experiment Details
ZIN Technologies Incorporated, Cleveland, OH, United States
Sponsoring Space Agency
National Aeronautics and Space Administration (NASA)
Human Exploration and Operations Mission Directorate (HEOMD)
ISS Expedition Duration
March 2010 - September 2010
Previous ISS Missions
This is the first mission for the IVGEN investigation. ^ back to top
- The Patient Condition Database (PCDB) provides a list of over four hundred medical conditions that may present and require treatment during long-duration space exploration. Of the conditions, approximately 25 percent may require medical fluids during the course of treatment. Operational constraints such as mass limitations and lack of refrigeration may limit the volume of such fluids that can be carried onboard spacecraft. Some conditions that may require fluid treatment include major bone fracture, burns, and acute anemia.
- Limitations on launch mass and available spacecraft volume restricts the amount of intravenous (IV) fluid that could be available during these missions. Additionally, prepackaged IV water would likely reach the expiration of shelf life before the end of long-duration exploration missions. As a result, NASA is developing hardware that can produce IV solution with cabin water as the feedstock. The IntraVenous Fluid GENeration for Exploration Missions (IVGEN) system requires much less mass and volume than an equivalent amount of prepackaged IV fluid.
IntraVenous Fluid GENeration for Exploration Missions (IVGEN) will demonstrate a microgravity compatible water purification and pharmaceutical mixing system. IVGEN utilizes a deionizing resin bed to remove contaminants from feedstock water to a purity level that meets the standards of the United States Pharmacopeia (USP), which is chartered by the United States Food and Drug Administration to function as the governing body for pharmaceuticals in the United States. The water will then be introduced into an intravenous (IV) bag where the fluid will be mixed with USP grade crystalline salt to produce USP normal saline. Inline conductivity sensors will quantify feedstock water quality, output water purity, and normal saline mixing uniformity.
The resin bed is made from 0.5 mm diameter beads packed into a cylinder including bubble-trapping hardware upstream from the filter to insure that no failures occur from trapping bubbles within the filter to insure optimal performance. The hardware will quantify system performance using flow and pressure transducers. If the hardware were to experience performance degradation, these transducers would allow the fluid physicists to identify and fix the problem.
IVGEN will operate in the Microgravity Sciences Glovebox (MSG) and will utilize cameras and video recording devices provided by that facility to observe system performance.
Due to mass and volume limitations, space vehicles cannot carry sufficient IV fluid for medical contingencies. A filtering and mixing system that can make IV fluid in situ would provide the treatment capability without the mass and volume constraints. IVGEN was designed and will be tested to meet that need.
IVGEN technology could be used on Earth to generate IV fluid in Third World countries where medical resources are limited.
IVGEN requires MSG resources such as electrical power, video capability, and data collection/transmission. IVGEN also requires access to pressurized nitrogen to pressurize the accumulator. IVGEN requires one 1.5 liter bag of IV fluid be returned in refrigerated stowage for ground-based analysis. IVGEN requires return of a second 1.5 liter bag of IV fluid, but it can remain ambient. Each IVGEN run will take approximately 1.5 hours, but does not require crew interaction for the duration of session.
Astronauts will install IVGEN in the MSG per procedures. The astronaut will transfer ISS water from an Iodine Crew Water Container (ICWC) to the IVGEN accumulator. When that is complete, the astronaut will pressurize the IVGEN accumulator with nitrogen. The pressure will force water through the IVGEN system, beginning with a bubble trap to eliminate unwanted air, and a conductivity sensor to quantify the quality of the incoming water. Following the conductivity sensor, the water will pass through the packed resin bed, through another bubble trap to remove any air that may have been present in the filter, and then into the mixing bag. The mixing bag will contain the salt required to make a saline solution, as well as a sterile magnetic stir bar. After the bag has been filled with 1.5 liters of water, the stir bar will mix the solution. Following mixing, the fluid will pass out of the mixing bag, through a conductivity sensor to measure uniformity, and into a final collection bag. After all of the solution is in the collection bag, it will be disconnected from the system, sealed, and appropriately stowed.
IVGEN generates intravenous (IV) fluid from ISS Water Processing Assembly (WPA) potable water using a water purification technique and pharmaceutical mixing system. The system operated onboard the ISS during May 2010 and produced six 1.5 liter bags of purified water. Two of these bags were mixed with sodium chloride to make 0.9 percent normal saline solution. These two bags were returned to Earth to test for contamination compliance with United States Pharmacopeia (USP) requirements. On-orbit results showed IVGEN met the experimental success criteria with the exception of the salt concentration. Problems with a large air bubble in the first bag of purified water resulted in a slightly too salty solution of 117 percent (USP permits a range from 95 to 105 percent of the target value) of the target value of 0.9 g/L. This problem can be resolved by placing a gas-liquid separator filter immediately upstream of the liquid inlet to the accumulator. The second bag didn’t have enough salt premeasured in the mixing bag resulting in a slightly low salt concentration of 93.8 percent of the target value. Improvements for an operational system are being carried out based on lessons learned from the ISS experiment and include testing of the purification capacity and shelf life storage technique for the deionization (DI) resin cartridges (McQuillen et al. 2011).
^ back to top
Ground Based Results Publications
Glenn researchers test the effectiveness of an IV fluid mixing method on NASA's zero-gravity aircraft (Credit: NASA).
+ View Larger Image
Planar Laser-Induced Fluorescence (PLIF) image of mixing pharmaceuticals and IV fluid (Credit: NASA).
+ View Larger Image